Patents Examined by Sharon Turner
-
Patent number: 7189529Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 25, 2001Date of Patent: March 13, 2007Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Sophia S. Kuo, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, David L. Shelton, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
-
Patent number: 7175988Abstract: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.Type: GrantFiled: February 8, 2002Date of Patent: February 13, 2007Assignee: Human Genome Sciences, Inc.Inventors: Viktor Roschke, Craig A. Rosen, Steven M. Ruben
-
Patent number: 7169783Abstract: The invention relates to an antagonist of one or more of Rho family members having ability to elicit neurite outgrowth from cultured neurons in an assay method which includes culturing neurons on a substrate that incorporates a growth-inhibiting amount of Rho family member and exposing the cultured neurons to a candidate Rho family member antagonist agent to permit neuron growth. Candidates which elicit neurite outgrowth from the cultured neurons are thus identified as Rho family antagonists.Type: GrantFiled: December 17, 2001Date of Patent: January 30, 2007Assignee: Universite de MontrealInventors: Lisa McKerracher, Maxime Lehmann
-
Patent number: 7160546Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: GrantFiled: September 3, 2002Date of Patent: January 9, 2007Assignee: Human Genome Sciences, Inc.Inventors: Yi Li, Steven M Ruben
-
Patent number: 7125687Abstract: The invention provides methods and compositions relating to pen polypeptides having pen-specific structure and activity, related polynucleotides and modulators of pen function. The invention provides isolated pen hybridization probes and primers capable of specifically hybridizing with natural pen genes, pen-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for pen transcripts), therapy (e.g. pen inhibitors to modulate APP processing) and in the biopharmaceutical industry (e.g. as immunogens, reagents for screening chemical libraries for lead pharmacological agents, etc.).Type: GrantFiled: May 5, 2000Date of Patent: October 24, 2006Assignee: Exelixis, Inc.Inventors: Daniel Tim Curtis, George Ross Francis, Michael Christopher Ellis, David Andrew Ruddy, Sharmon Monique Nicoll, Garth Joseph McGrath
-
Patent number: 7109319Abstract: The invention provides isolated nucleic acid molecules, designated FAIL, which encode polypeptide molecules containing Ig and Ig-like domains and which are homologous to Fc?RI. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 10, 2003Date of Patent: September 19, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventor: Christopher C. Fraser
-
Patent number: 7105640Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 19, 2001Date of Patent: September 12, 2006Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7098304Abstract: The invention concerns peptides which bind antibodies that are found in elevated levels in body fluids of schizophrenic patients and are found at a lower level or not found at all in body fluids of non-schizophrenic individuals. Using a computerized program, the antigenic epitope of the peptides of the invention is predicted as having a core of hydrophobic amino acids which is surrounded by positively charged amino acids. The peptides of the invention are useful in the diagnosis of schizophrenia in an individual.Type: GrantFiled: March 30, 1999Date of Patent: August 29, 2006Assignee: Yeda Research and Development Co. Ltd.Inventors: Meir Shinitzky, Michael Deckmann
-
Patent number: 7090987Abstract: The invention features methods of diagnosing and treating a patient having Alzheimer's disease or other neuronal atrophy-associated dementia by determining or altering, respectively, the level of activity of pathways from the endoplasmic reticulum to lysosomes in the patient.Type: GrantFiled: April 28, 2000Date of Patent: August 15, 2006Inventors: Ralph A. Nixon, Anne M. Cataldo, Paul M. Mathews
-
Patent number: 7090985Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.Type: GrantFiled: December 3, 2002Date of Patent: August 15, 2006Assignee: UCB, S.A.Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
-
Patent number: 7087404Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: December 12, 2001Date of Patent: August 8, 2006Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Dan L. Eaton, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7067473Abstract: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.Type: GrantFiled: July 14, 1999Date of Patent: June 27, 2006Assignee: Janssen Pharmaceutica N.V.Inventor: Stefan Leo Jozef Masure
-
Patent number: 7060676Abstract: The invention relates to T. cruzi trans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and/or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and/or neurotrophic peptide. TS, IL-6 secretion-inducing variants and/or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and/or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides.Type: GrantFiled: December 20, 2000Date of Patent: June 13, 2006Assignee: Trustees of Tufts CollegeInventors: Marina Chuenkova, Miercio A. Pereira
-
Patent number: 7060270Abstract: This invention provides methods and compositions for the detection, diagnosis and treatment of amyloid-associated diseases, in particular, diseases comprising deposition of amyloid assemblies, fibrils, filaments, tangles, or plaques. A preferred composition comprises monoclonal antibodies that specifically bind amyloid proteins, peptides or fragments and change the conformation.Type: GrantFiled: November 4, 2002Date of Patent: June 13, 2006Assignee: Diagenics International CorporationInventors: Yves Claude Nicolau, Ruth Greferath
-
Patent number: 7060457Abstract: In one aspect, the present invention features methods for detecting at least one neurological disorder in a patient, the method comprising obtaining a biological sample from the patient; and detecting at least one aberrant human glutamate transporter 2 (EAAT 2) mRNA in the sample as being indicative of the neurological disorder in the patient. In a particular aspect, the invention is useful for detecting amyotrophic lateral sclerosis (ALS) in the patient.Type: GrantFiled: March 18, 1998Date of Patent: June 13, 2006Assignee: Johns Hopkins UniversityInventors: Jeffrey D. Rothstein, Chieng-Liang Glenn Lin, Lynn A. Bristol
-
Patent number: 7041473Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cell and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.Type: GrantFiled: April 12, 2000Date of Patent: May 9, 2006Assignee: Pharmacia & Upjohn CompanyInventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
-
Patent number: 7018839Abstract: The acetylcholinesterase 14-mer peptide AEFHRWSSYMVHWK acts alone or in synergism with 2-amyloid to contribute to neuronal degeneration, e.g. in Parkinson's and Alzheimer's diseases, perhaps by exerting calcium channel opening activity. Antibodies and other compounds which inhibit the biological activity are useful for prophylaxis or treatment.Type: GrantFiled: March 21, 1997Date of Patent: March 28, 2006Assignee: Synaptica LimitedInventors: Susan Adele Greenfield, David John Talbutt Vaux
-
Patent number: 7005411Abstract: The amount of active Robo expressed on a cell is modified by modulating the effective amount of a Comm polypeptide in contact with the cell, whereby the amount of expressed active Robo is modulated inversely with the modulation of the effective amount of the Comm polypeptide in contact with the cell. In a particular embodiment, the Comm polypeptide is provided to the cell by exogenously in a pharmaceutically acceptable composition. In another aspect, the invention provides methods of screening for agents which modulate Robo-Comm interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Comm polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell.Type: GrantFiled: November 13, 1998Date of Patent: February 28, 2006Assignee: Regents of the University of CaliforniaInventors: Corey S. Goodman, Thomas Kidd, Guy Tear, Claire Russell, Kevin J. Mitchell
-
Patent number: 6906169Abstract: The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid ? (A?) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the A? peptide and generate antibodies, which are highly cross-reactive to the soluble A?1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble A?1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the “soluble A?-derived toxins”; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain.Type: GrantFiled: May 25, 2001Date of Patent: June 14, 2005Assignee: United Biomedical, Inc.Inventor: Chang Yi Wang
-
Patent number: 6890516Abstract: Methods of assessing the effect of a drug on long term memory and for screening a pharmaceutical agent for its ability to modulate long term memory are disclosed.Type: GrantFiled: October 14, 1999Date of Patent: May 10, 2005Assignee: Cold Spring Harbor LaboratoryInventors: Timothy P. Tully, Jerry Chi-Ping Yin